Hemetron ^Company

Over 100 million people globally suffer from Inflammatory Rheumatic Diseases (IRD), causing chronic pain, fatigue, and flare-ups that significantly reduce quality of life. Traditional monitoring, with doctor visits every 3-6 months, leaves gaps in tracking disease progression, leading to poor outcomes and suffering. Hemetron AG addresses this problem with a groundbreaking remote monitoring system, enabling patients to conduct at-home blood tests. Results are digitally sent to physicians for timely treatment adjustments. This solution improves disease tracking, patient engagement, and reduces costs. We revolutionize chronic patient care through more personalized and effective treatments, delivering better outcomes at lower costs.